Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial
17. Dezember 2024 08:37 ET
|
Psyence Biomedical Ltd.
Patient screening underway; first patient expected to be randomized into the study in January A leading clinical trial site management organization (SMO), Australian Clinical Trial Network (ACTioN),...
Psyence Biomed Executes Binding Agreements with Optimi Health Corp.
10. Dezember 2024 07:30 ET
|
Psyence Biomedical Ltd.
NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence Biomed" or the "Company") today announced that it has progressed beyond the previously-announced...
Psyence Biomedical Issues Shareholder Update Highlighting Recent Progress
03. Dezember 2024 07:30 ET
|
Psyence Biomedical Ltd.
Independent valuation of PsyLabs values Psyence Biomed’s stake at approximately $2 million, doubling in value Debt-for-equity swap with Psyence Group and Newcourt SPAC Sponsor results in strengthened...
Psyence Biomedical Announces Favorable Result of Nasdaq Listing Qualifications Hearing
20. November 2024 07:30 ET
|
Psyence Biomedical Ltd.
NEW YORK, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced the favorable outcome of the Nasdaq Listing Qualifications...
Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation
19. November 2024 16:05 ET
|
Psyence Biomedical Ltd.
NEW YORK, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced an effective date for its previously-announced share...
Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq
12. November 2024 16:30 ET
|
Psyence Biomedical Ltd.
NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced the voting results for each of the matters presented at the...
Psyence Biomedical Announces Closing of Previously Announced Acquisition of Psyence Group’s Stake in PsyLabs
31. Oktober 2024 07:30 ET
|
Psyence Biomedical Ltd.
PsyLabs develops and produces certified pharmaceutical-grade nature-derived psychedelics for applications in mental health and well-being Psyence Biomedical has issued common shares to...
Psyence Biomed Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care
24. Oktober 2024 07:00 ET
|
Psyence Biomedical Ltd.
Empax Center brings significant expertise in clinical trial execution for mental health and neurological conditions Psyence Biomed on track to begin recruitment this quarter, and to announce...
Psyence Biomed Provides Progress Update on PsyLabs E.U. Good Manufacturing Practices (GMP) Certified Active Pharmaceutical Ingredient (API) Development
17. Oktober 2024 07:00 ET
|
Psyence Biomedical Ltd.
NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence Biomed" or the "Company") is pleased to provide an update on its previously-announced pending strategic...
Psyence Biomed Provides Update on Previously Announced Acquisition of Clairvoyant
04. Oktober 2024 16:05 ET
|
Psyence Biomedical Ltd.
NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence Biomed" or the "Company"), a developer of psilocybin-based therapeutics, today provided an update on its...